Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern

Journal of Cutaneous Pathology

Volumn 45, Issue 7, 2018, Pages 504-507

  Trinidad, Celestine ^a,b   Nelson, Kelly C ^c   Glitza Oliva, Isabella C ^a   Torres Cabala, Carlos A ^a   Nagarajan, Priyadharsini ^a   Tetzlaff, Michael T ^a   Ivan, Doina ^a,c   Hwu, Wen Jen ^a   Prieto, Victor G ^a,b   Curry, Jonathan L ^a,b   Aung, Phyu P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^c University of Texas Health Science Center at Houston   (United States)

Author keywords

granulomatous dermatitis; immune checkpoint blockade therapy; melanoma

Indexed keywords

IPILIMUMAB; MONOCLONAL ANTIBODY; PEMBROLIZUMAB;

AGED; CASE REPORT; DRUG ERUPTION; HUMAN; IMMUNOTHERAPY; MALE; MELANOMA; PATHOLOGY; SKIN TUMOR;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ERUPTIONS; HUMANS; IMMUNOTHERAPY; IPILIMUMAB; MALE; MELANOMA; SKIN NEOPLASMS;

EID: 85048707368     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.13150     Document Type: Article

References (17)

1. Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43(8):688-696.
2. Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158-176.
3. Ciccarese C, Alfieri S, Santoni M, et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(1):57-75.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
5. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-2532.
6. Long GV, Atkinson V, Cebon JS, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017;18(9):1202-1210.
7. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol. 2015;11(17):2471-2484.
8. Wu J, Kwong BY, Martires KJ, et al. Granuloma annulare associated with immune checkpoint inhibitors. J Eur Acad Dermatol Venereol. 2018;32(4):e124-e126.
9. Kaunitz GJ, Loss M, Rizvi H, et al. Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern. Am J Surg Pathol. 2017;41(10):1381-1389.
10. Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol. 1998;25(2):72-78.
11. Perrin C, Lacour JP, Castanet J, Michiels JF. Interstitial granulomatous drug reaction with a histological pattern of interstitial granulomatous dermatitis. Am J Dermatopathol. 2001;23(4):295-298.
12. Laura A, Luca P, Luisa PA. Interstitial granulomatous drug reaction due to febuxostat. Indian J Dermatol Venereol Leprol. 2014;80(2):182-184.
13. Tan EST, Robson A, Lai-Cheong JE, Wain EM. Interstitial granulomatous drug reaction induced by quetiapine. Clin Exp Dermatol. 2016;41(2):210-211.
14. Martín G, Cañueto J, Santos-Briz A, Alonso G, Unamuno PD, Cruz JJ. Interstitial granulomatous dermatitis with arthritis associated with trastuzumab. J Eur Acad Dermatol Venereol. 2010;24(4):493-494.
15. Martínez-Morán C, Nájera L, Ruiz-Casado AI, et al. Interstitial granulomatous drug reaction to sorafenib. Arch Dermatol. 2011;147(9):1118-1119.
16. Frauchiger AL, Brüggen MC, Goldinger SM, Dummer R. Interstitial granulomatous dermatitis during talimogen laherparepvec treatment. Melanoma Res. 2017;27(4):400-401.
17. Everett AS, Pavlidakey PG, Contreras CM, et al. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases. J Cutan Pathol. 2018;45(1):48-53.